Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen

• Published in: ACS medicinal chemistry letters Vol. 12; no. 1; pp. 99 - 106
• Main Authors: Bukhtiyarova, Marina, Cook, Erica M, Hancock, Paula J, Hruza, Alan W, Shaw, Anthony W, Adam, Gregory C, Barnard, Richard J O, McKenna, Philip M, Holloway, M Katharine, Bell, Ian M, Carroll, Steve, Cornella-Taracido, Ivan, Cox, Christopher D, Kutchukian, Peter S, Powell, David A, Strickland, Corey, Trotter, B Wesley, Tudor, Matthew, Wolkenberg, Scott, Li, Jing, Tellers, David M
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 14-01-2021
• Subjects: Letter
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/acsmedchemlett.0c00551

By employing a phenotypic screen, a set of compounds, exemplified by
, were identified which potentiate the ability of histone deacetylase inhibitor vorinostat to reverse HIV latency. Proteome enrichment followed by quantitative mass spectrometric analysis employing a modified analogue of
as affinity bait identified farnesyl transferase (FTase) as the primary interacting protein in cell lysates. This ligand-FTase binding interaction was confirmed via X-ray crystallography and temperature dependent fluorescence studies, despite
lacking structural and binding similarity to known FTase inhibitors. Although multiple lines of evidence established the binding interaction, these ligands exhibited minimal inhibitory activity in a cell-free biochemical FTase inhibition assay. Subsequent modification of the biochemical assay by increasing anion concentration demonstrated FTase inhibitory activity in this novel class. We propose
binds together with the anion in the active site to inhibit farnesyl transferase. Implications for phenotypic screening deconvolution and HIV reactivation are discussed.